JEV

Securing Success with Patent Protection and an IP Edge

Retrieved on: 
Saturday, September 16, 2023
Hydrogen, Communication, Head Injuries, Apple Inc., Data science, Marketing, Electricity, Microsoft, Apple Watch, Computer, Patent, Investment, Risk, Iberdrola, Publishing, News, Software, Advertising, IPhone, GPS, University, Interview, Litigation involving Apple Inc., Skiing, JEV, Research, Broker-dealer, SEDAR, Apple, Growth, Use, Disclaimer, Hydrogen technologies, Carbon, Government, AAPL, Climate change, Traction, Rystad Energy, MSFT, Partnership, File, Bank statement, Information Bridge: Department of Energy Scientific and Technical Information, Crash, OTC, AI, Health, Video game, Renewable energy, Oil, Cryptocurrency, Exogen, EU, AirPods, Avangrid

That's why Jericho Energy Ventures (TSX.V: JEV) (OTC: JROOF) is thrilled to obtain patent approval for its subsidiary’s hydrogen-fueled steam boiler.

Key Points: 
  • That's why Jericho Energy Ventures (TSX.V: JEV) (OTC: JROOF) is thrilled to obtain patent approval for its subsidiary’s hydrogen-fueled steam boiler.
  • These patents not only recognize their innovations but also give them a competitive industry edge.
  • This is the third patent Hydrogen Technologies has in the pipeline as the company begins to receive initial commercial orders.
  • Apple Inc's (NASDAQ: AAPL) new patent application suggests enhancing Crash Detection accuracy by integrating multiple Apple devices, notably using motion sensors in AirPods.

Jericho Energy Ventures Inc.: Unleashing the Power of Green Hydrogen: A Hot Investment Trend

Retrieved on: 
Thursday, July 13, 2023
Hydrogen, News, Jacobs Solutions, Fortescue Metals Group, Communication, Advertising, Aberdeen City Council, Partnership, EU, Interview, Exogen, Metal, Use, Disclaimer, Marketing, Aluminium, Bank statement, JLM, Risk, JEV, Research, Hydrogen technologies, Recycling, FRA, Carbon, Government, Organization, Steam, Iron, Investment, Engineering, Natural gas, OTC, SEDAR, FFI, CO2, Growth, Transport, Publishing, NYSE, Renewable energy, Security (finance), Norsk Hydro, BP

Jericho Energy Ventures Inc.: Unleashing the Power of Green Hydrogen: A Hot Investment Trend

Key Points: 
  • Jericho Energy Ventures Inc.: Unleashing the Power of Green Hydrogen: A Hot Investment Trend
    The issuer is solely responsible for the content of this announcement.
  • Together, these collaborations signify an industry-wide commitment to sustainable energy practices and signal a promising future for the green hydrogen movement.
  • The HSP3000 features the patented DCC™ boiler technology developed by Hydrogen Technologies, a wholly-owned subsidiary of Jericho Energy Ventures.
  • This partnership underpins the shared commitment to renewable energy, supporting FFI’s global green hydrogen and renewable energy projects, aimed at decarbonizing heavy industries.

Jericho Energy Ventures to Present at the Sequire Investor Summit in Puerto Rico

Retrieved on: 
Tuesday, April 18, 2023
La Concha Renaissance San Juan Resort, Knowledge, JEV

Newtown, PA, April 18, 2023 (GLOBE NEWSWIRE) -- Jericho Energy Ventures Inc. (TSXV: JEV; OTC: JROOF) (“JEV”) is proud to announce its participation at the upcoming Sequire Investor Summit.

Key Points: 
  • Newtown, PA, April 18, 2023 (GLOBE NEWSWIRE) -- Jericho Energy Ventures Inc. (TSXV: JEV; OTC: JROOF) (“JEV”) is proud to announce its participation at the upcoming Sequire Investor Summit.
  • Brian Williamson, Jericho Energy Ventures’ CEO, will present on Tuesday April 25 at 2pm ET.
  • JEV is thrilled to participate in this year's Sequire Investor Summit and looks forward to sharing its knowledge and expertise with attendees.
  • For more information about the Sequire Investor Summit, including registration details, please visit the official event website at https://puertorico.srax.com/

CEPI partners with Tiba Biotech to evaluate next-generation RNA vaccine platform technology to respond to 'Disease X'

Retrieved on: 
Thursday, January 12, 2023
Fever Dream, CEPI, Reactogenicity, Fever, COVID-19, RNA transfection, Yellow fever, G7, LNP, Vaccine, Coalition for Epidemic Preparedness Innovations, Equitable, Partnership, Disease, Refrigeration, RNA, Mortality, Flavivirus, Epidemic, Coalition, US, Venezuelan equine encephalitis virus, Policy, JEV, Control

OSLO Norway and CAMBRIDGE, Mass., Jan. 12, 2023 /PRNewswire/ -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Tiba Biotech , a preclinical biopharmaceutical company, today announced a new partnership agreement to evaluate Tiba Biotech's next-generation RNA vaccine platform technology.

Key Points: 
  • OSLO Norway and CAMBRIDGE, Mass., Jan. 12, 2023 /PRNewswire/ -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Tiba Biotech , a preclinical biopharmaceutical company, today announced a new partnership agreement to evaluate Tiba Biotech's next-generation RNA vaccine platform technology.
  • Tiba Biotech's innovative platform could offer substantial advantages over existing RNA vaccines when responding to future epidemic or pandemic diseases.
  • CEPI will provide US$2 million to advance Tiba Biotech's novel RNA nanoparticle delivery platform, RNABL™.
  • To deliver an RNA payload, Tiba Biotech uses organic molecules to form biodegradable nanoparticles that are less inflammatory than current lipid nanoparticle (LNP) formulations.

SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines

Retrieved on: 
Tuesday, October 25, 2022
Lassa mammarenavirus, Bill, RNA transfection, Pandemic, Second, CEPI, GIA, Virus, CMV, Ministry of Health and Welfare (South Korea), JEV, Vaccine, Organization, Foundation, RSV, SK, RNA, MOHW, Equitable, Partnership, Technology, Infection, Epidemic, Company, Public health, Health, CEO, Ministry, Park Min-soo, Coalition, Control, COVID-19, USD, Policy, Pharmaceutical industry

USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil.

Key Points: 
  • USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil.
  • Under the agreement, SK bioscience will receive up to 140 million USD in R&D expenses from CEPI.
  • Earlier, SK bioscience had the partnership with the Bill & Melinda Gates Foundation in order to build the mRNA vaccine platform.
  • CEPI and SK bioscience are committed to enabling global equitable access to the vaccines they develop.

Lehigh Hanson Strengthens Recycling Business in the Pacific Northwest

Retrieved on: 
Tuesday, October 4, 2022
Solution, JEV, CEO, Recycling, Acquisition, Building material, Pacific Northwest, GLOBE, Seattle metropolitan area

The acquisition of JEV Recycling represents an important step for Lehigh Hanson as we grow our business beyond cement and aggregates while working to lower our environmental footprint, said Chris Ward, President and CEO of Lehigh Hanson and Member of the Managing Board of Heidelberg Materials.

Key Points: 
  • The acquisition of JEV Recycling represents an important step for Lehigh Hanson as we grow our business beyond cement and aggregates while working to lower our environmental footprint, said Chris Ward, President and CEO of Lehigh Hanson and Member of the Managing Board of Heidelberg Materials.
  • Lehigh Hanson also recently added a new concrete recycling plant to its Cadman, Inc. operations in Redmond, Wash.
  • We are pleased by the progress we are making to grow our recycling businesses in the Pacific Northwest, said Oliver Patsch, President of Lehigh Hansons Canada Region.
  • Soon to become Heidelberg Materials, Lehigh Hanson provides customers with solutions born out of creative thinking and approached with enthusiasm.

NanoView Biosciences Announces Key Appointments to Scientific Advisory Board

Retrieved on: 
Thursday, August 19, 2021
Company, IPSC, Journal, University, Lysogenic cycle, Cancer, Prognosis, ISEV, Research, Diagnosis, Exosome, Biomarker, RNA, Culture Collection (University of Gothenburg), Disease, JEV, Therapy, Central nervous system, Seminal vesicles, Cell, Inflammation, Nanomedicine, Coronavirus Scientific Advisory Board (Turkey), International Society, International Society for Extracellular Vesicles, DVM, Patient, Journal of Extracellular Vesicles, CEO, Pharmacology, Technology, Pharmaceutical industry

BOSTON, Aug. 19, 2021 /PRNewswire/ --NanoView Biosciences today announced the appointment of Prof. Jan Ltvall, M.D., Ph.D., and Mark Plavsic, DVM, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • BOSTON, Aug. 19, 2021 /PRNewswire/ --NanoView Biosciences today announced the appointment of Prof. Jan Ltvall, M.D., Ph.D., and Mark Plavsic, DVM, Ph.D., to its Scientific Advisory Board.
  • Jan Ltvall is a Professor at the University of Gothenburg in Sweden where he directs a research laboratory studying extracellular vesicles.
  • He is a medical specialist in both Clinical Allergy and Clinical Pharmacology, and has extensive experience in translational studies in inflammation and cancer.
  • I am excited to advise NanoView as it delivers unique products and services to advance this rapidly expanding field of nanomedicine," stated Prof. Ltvall.